Based on what little I know about the way Hollywood works (Julia Boorstin's our go-to reporter on that stuff), when I saw that CBS Films was releasing "Extraordinary Measures" in January, I assumed that couldn't be a good sign.
I'm on my way back from the JPMorgan Healthcare Conference in San Francisco. Oh, it's still going on for another day-and-a-half or so, but two days is about all I can take.
A group of House lawmakers and the head of the Federal Trade Commission want Congress to include a provision in the health care legislation that they say could save American consumers several billion dollars a year on prescription drugs.
Investors should continue to invest in defensive stocks in strong dividend sectors like telecommunications, technology and pharmaceuticals, said Willem Nabarro, head of European equities for Asia at Exane-BNP Paribas on Tuesday.
Vivus is getting the JPMorgan Healthcare Conference off to a sexy start. The company announced this morning that its late-stage experimental erectile dysfunction drug apparently gets the job done in 15 minutes.
I'm gonna avoid all the cliches about JPM being the Super Bowl of investment conferences or the grandaddy of them all. As of earlier this week, JPM says 6,500 people are expected to attend (down slightly from last year,) more than 330 public and private companies are presenting and more than 7,500 so-called one-on-one meetings between analysts/investors and execs have been scheduled. Plus, a whole bunch of other meetings take place on the down low all over the city.
I've always wanted go to Robert Redford's star-studded "independent" film festival in Utah. And, now, I might have a legitimate excuse to get CNBC to pay for it.
GlaxoSmithKline can fuggedaboutit. If New York radio listeners have a problem with the company's new ad campaign for Nicorette, then how will it possibly play in Peoria?
For Cephalon, a company in Frazer, Pa., whose business tactics have attracted federal attention, the approval for jet lag is part of a plan to extend patent protection for its core franchise in stay-awake drugs.
GlaxoSmithKline is getting into the movie business, pursuing an unusual and most likely controversial strategy to increase interest in a weight-loss drug. The New York Times reports.
No one in their right mind, especially in this economy, likes to see someone lose their job. (Well, unless you really can't stand the person.) But, on the other hand, when you hear the top exec of the world's biggest drug company talk candidly about how much fat there was (is?) at Pfizer, can you really blame him for swinging the ax?
Talk about a blow to the ego. The shares may have since succumbed to the downdraft in the overall stock market, but when trading opened this morning Biogen Idec shot up around two percent. Investors were reacting to the news that the company's longtime CEO, Jim Mullen, is calling it quits.
Time magazine's Man of the Year Ben Bernanke gave a speech this past weekend, and at first I thought he was defending the excessively loose monetary policy that led to the recent crisis.
Well, that didn't take long. It's only the first business day of the new year and big pharma's already gettin' down to business. Novartis is buying the rest of its Swiss neighbor Alcon for a cool $38.5 billion.
Usually I wouldn’t devote a blog to a biotech with a market value of approximately $86 million. But when your personal story goes Hollywood—as in mega-watt stars like Harrison Ford and Brendan Fraser playing the lead roles in the movie—then you get a blog.
Markets held gains on Tuesday after reports showed US home prices stabilized and consumer confidence improved. What should investors expect in the New Year and how should they be positioned? Tobias Levkovich, chief U.S. equity strategist at Citigroup, shared his strategies.
When I blogged last week about GlaxoSmithKline using the word “suck” in its new Nicorette ad campaign I thought it would be a one and done thing.
Stocks closed higher as a holiday rally got a further push from big technology, banks and commodities, though most investors took Christmas Eve off.
Futures mostly shrugged off news that weekly unemployment claims hit their lowest level in 15 months, but stocks were still poised for a gain in a holiday-shortened session Thursday.
Plus, get calls on the BlackBerry outage, pharma, dividends and more.